» Articles » PMID: 37578485

Vaso-occlusive Crisis Pain Intensity, Frequency, and Duration: Which Best Correlates with Health-related Quality of Life in Adolescents and Adults with Sickle Cell Disease?

Overview
Journal Pain
Specialties Neurology
Psychiatry
Date 2023 Aug 14
PMID 37578485
Authors
Affiliations
Soon will be listed here.
Abstract

In a cross-sectional analysis of baseline data from a randomized clinical trial, we studied 198 adolescents and adults aged 15+ with sickle cell disease. Interest was in assessing the relative strengths of the relationship of vaso-occlusive crisis (VOC) pain domains of intensity, frequency, and duration, with health-related quality of life (HRQOL). Variation in psychosocial, physical function, and pain expression domains of HRQOL was partially explained by frequency, intensity, and duration of VOC pain, separately and together, over and above differences in age, sex, genotype, and organ system damage. However, no single domain measure accounted for more than an additional partial R2 of 12.5% alone. Vaso-occlusive crisis pain frequency explained the most variation, when simultaneously considering VOC intensity and duration, except for stiffness , where duration was most predictive. Yet VOC pain intensity, and even VOC duration, also contributed to variability in HRQOL. We recommend that for most purposes, because all 3 VOC pain domains contribute to variability in HRQOL, all 3 domains should be assessed and interventions should be targeted to improve all 3 domains to maximize HRQOL outcomes (Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT02197845 ).

Citing Articles

Clinical Insights into Sickle Cell Disease: A Comprehensive Multicenter Retrospective Analysis of Clinical Characteristics and Outcomes Across Different Age Groups.

Almarghalani D, Alotaibi R, Alzlami T, Alhumaidi O, Alharthi N, Alboqami F J Clin Med. 2024; 13(23).

PMID: 39685683 PMC: 11641892. DOI: 10.3390/jcm13237224.


Evaluation of peripheral blood inflammatory biomarkers in sickle cell disease with and without retinopathy.

Ozer O, Dogan L, Baysal Z, Basir H, Ciftci A, Eroz P Graefes Arch Clin Exp Ophthalmol. 2024; 262(12):3787-3796.

PMID: 38976013 PMC: 11608169. DOI: 10.1007/s00417-024-06569-9.

References
1.
Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

2.
Anie K, Steptoe A, Bevan D . Sickle cell disease: Pain, coping and quality of life in a study of adults in the UK. Br J Health Psychol. 2003; 7(Part 3):331-344. DOI: 10.1348/135910702760213715. View

3.
Field J, Ballas S, Campbell C, Crosby L, Dampier C, Darbari D . AAAPT Diagnostic Criteria for Acute Sickle Cell Disease Pain. J Pain. 2018; 20(7):746-759. DOI: 10.1016/j.jpain.2018.12.003. View

4.
Sil S, Cohen L, Bakshi N, Watt A, Hathaway M, Abudulai F . Changes in Pain and Psychosocial Functioning and Transition to Chronic Pain in Pediatric Sickle Cell Disease: A Cohort Follow-up Study. Clin J Pain. 2020; 36(6):463-471. PMC: 7233325. DOI: 10.1097/AJP.0000000000000827. View

5.
McClish D, Smith W, Levenson J, Aisiku I, Roberts J, Roseff S . Comorbidity, Pain, Utilization, and Psychosocial Outcomes in Older versus Younger Sickle Cell Adults: The PiSCES Project. Biomed Res Int. 2017; 2017:4070547. PMC: 5387810. DOI: 10.1155/2017/4070547. View